Identification

Name
Sorafenib
Accession Number
DB00398  (APRD01304, DB07438)
Type
Small Molecule
Groups
Approved, Investigational
Description

Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

Structure
Thumb
Synonyms
  • 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
  • N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
  • Sorafenibum
External IDs
BAY 43-9006 / BAY-43-9006
Product Ingredients
IngredientUNIICASInChI Key
Sorafenib Tosylate5T62Q3B36J475207-59-1IVDHYUQIDRJSTI-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NexavarTablet, film coated200 mg/1OralBayer2005-12-20Not applicableUs50419 0488 58 nlmimage10 1c190e68
NexavarTablet, film coated200 mgOralBayer Pharma Ag2006-07-19Not applicableEu
NexavarTablet200 mgOralBayer2006-07-31Not applicableCanada
Categories
UNII
9ZOQ3TZI87
CAS number
284461-73-0
Weight
Average: 464.825
Monoisotopic: 464.08630272
Chemical Formula
C21H16ClF3N4O3
InChI Key
MLDQJTXFUGDVEO-UHFFFAOYSA-N
InChI
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
IUPAC Name
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
SMILES
CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1

Pharmacology

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

Structured Indications
Pharmacodynamics

No large changes in QTc interval were observed. After one 28-day treatment cycle, the largest mean QTc interval change of 8.5 ms (upper bound of two-sided 90% confidence interval, 13.3 ms) was observed at 6 hours post-dose on day 1 of cycle 2.

Mechanism of action

Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited.

TargetActionsOrganism
ASerine/threonine-protein kinase B-raf
inhibitor
Human
ARAF proto-oncogene serine/threonine-protein kinase
inhibitor
Human
AVascular endothelial growth factor receptor 3
antagonist
Human
AVascular endothelial growth factor receptor 2
antagonist
Human
AReceptor-type tyrosine-protein kinase FLT3
antagonist
Human
APlatelet-derived growth factor receptor beta
antagonist
Human
AMast/stem cell growth factor receptor Kit
antagonist
Human
AFibroblast growth factor receptor 1
inhibitor
Human
AProto-oncogene tyrosine-protein kinase receptor Ret
inhibitor
Human
AVascular endothelial growth factor receptor 1
inhibitor
Human
Absorption

The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma levels in 3 hours following oral administration. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.

Volume of distribution
Not Available
Protein binding

99.5% bound to plasma proteins.

Metabolism

Sorafenib is metabolized primarily in the liver, undergoing oxidative metabolism, mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9. Sorafenib accounts for approximately 70-85% of the circulating analytes in plasma at steady- state. Eight metabolites of sorafenib have been identified, of which five have been detected in plasma. The main circulating metabolite of sorafenib in plasma, the pyridine N-oxide, shows in vitro potency similar to that of sorafenib. This metabolite comprises approximately 9-16% of circulating analytes at steady-state.

Route of elimination

Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of the dose excreted in urine as glucuronidated metabolites.

Half life

25-48 hours

Clearance
Not Available
Toxicity

The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Sorafenib Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Sorafenib can be increased when it is combined with Abiraterone.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Sorafenib.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sorafenib.Approved
AcetaminophenAcetaminophen may increase the hepatotoxic activities of Sorafenib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sorafenib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Sorafenib.Experimental
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Sorafenib.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Sorafenib.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Sorafenib.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Sorafenib.Approved, Illicit, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sorafenib.Approved, Withdrawn
AmiodaroneThe serum concentration of Sorafenib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Sorafenib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Sorafenib.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Sorafenib.Approved
AnagrelideSorafenib may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sorafenib.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Sorafenib.Approved
AprepitantThe serum concentration of Sorafenib can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Sorafenib.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sorafenib.Approved, Investigational
Arsenic trioxideSorafenib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherSorafenib may increase the QTc-prolonging activities of Artemether.Approved
AsenapineSorafenib may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Sorafenib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Sorafenib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Sorafenib is combined with Atorvastatin.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Sorafenib.Approved
AzithromycinSorafenib may increase the QTc-prolonging activities of Azithromycin.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Sorafenib.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Sorafenib.Investigational
BedaquilineSorafenib may increase the QTc-prolonging activities of Bedaquiline.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Sorafenib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sorafenib.Approved
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Sorafenib.Approved, Investigational
BoceprevirThe serum concentration of Sorafenib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Sorafenib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sorafenib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sorafenib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Sorafenib.Approved, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sorafenib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sorafenib.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sorafenib.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Sorafenib.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sorafenib.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sorafenib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Sorafenib.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Sorafenib.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Sorafenib.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Sorafenib.Approved
CarbamazepineThe serum concentration of Sorafenib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sorafenib.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Sorafenib is combined with Carboplatin.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sorafenib.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sorafenib.Approved, Investigational
CeritinibThe serum concentration of Sorafenib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Sorafenib.Withdrawn
ChloroquineSorafenib may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineSorafenib may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Sorafenib.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Sorafenib.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sorafenib.Approved, Investigational
CiprofloxacinSorafenib may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideSorafenib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramSorafenib may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe serum concentration of Sorafenib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Sorafenib can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Sorafenib.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Sorafenib.Investigational
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Sorafenib.Approved, Nutraceutical
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sorafenib.Approved
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Sorafenib.Approved, Illicit
ClotrimazoleThe metabolism of Sorafenib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Sorafenib is combined with Clozapine.Approved
CobicistatThe serum concentration of Sorafenib can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sorafenib.Approved
ConivaptanThe serum concentration of Sorafenib can be increased when it is combined with Conivaptan.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sorafenib.Approved
CrisaboroleThe metabolism of Sorafenib can be decreased when combined with Crisaborole.Approved
CrizotinibSorafenib may increase the QTc-prolonging activities of Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sorafenib.Approved, Investigational
CyclosporineThe metabolism of Sorafenib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Sorafenib.Experimental
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sorafenib.Approved
DabrafenibThe serum concentration of Sorafenib can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe serum concentration of Dacarbazine can be decreased when it is combined with Sorafenib.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Sorafenib.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Sorafenib.Approved, Investigational
DarunavirThe serum concentration of Sorafenib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Sorafenib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Sorafenib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sorafenib can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Sorafenib.Approved
DesipramineThe metabolism of Sorafenib can be decreased when combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sorafenib.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sorafenib.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Sorafenib.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sorafenib.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Sorafenib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Sorafenib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sorafenib.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sorafenib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sorafenib.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Sorafenib.Experimental
DihydroergotamineThe metabolism of Sorafenib can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Sorafenib can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Sorafenib.Approved
DisopyramideSorafenib may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Sorafenib.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Sorafenib.Approved, Investigational
DofetilideSorafenib may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronSorafenib may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneSorafenib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Sorafenib.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Sorafenib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Sorafenib.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Sorafenib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sorafenib.Approved, Investigational
DoxorubicinThe metabolism of Sorafenib can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Sorafenib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sorafenib.Approved, Illicit
DronedaroneSorafenib may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolSorafenib may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Sorafenib.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Sorafenib.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Sorafenib.Approved, Investigational
EliglustatSorafenib may increase the QTc-prolonging activities of Eliglustat.Approved
EltrombopagThe serum concentration of Sorafenib can be increased when it is combined with Eltrombopag.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Sorafenib.Approved
EnzalutamideThe serum concentration of Sorafenib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Sorafenib.Approved, Investigational
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Sorafenib.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sorafenib.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sorafenib.Approved
ErythromycinSorafenib may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramSorafenib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Sorafenib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Sorafenib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Sorafenib.Approved, Illicit
EtodolacThe metabolism of Etodolac can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sorafenib.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Sorafenib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sorafenib.Approved
FelodipineThe metabolism of Sorafenib can be decreased when combined with Felodipine.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.Approved
FingolimodSorafenib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideSorafenib may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluconazoleThe metabolism of Sorafenib can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sorafenib.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sorafenib.Approved, Illicit
FluorouracilThe serum concentration of Fluorouracil can be decreased when it is combined with Sorafenib.Approved
FluoxetineSorafenib may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolSorafenib may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Sorafenib.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sorafenib.Approved
FluvoxamineThe metabolism of Sorafenib can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Sorafenib.Approved, Investigational
FosamprenavirThe metabolism of Sorafenib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sorafenib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Sorafenib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Sorafenib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Sorafenib.Investigational
Gadobenic acidSorafenib may increase the QTc-prolonging activities of Gadobenic acid.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Sorafenib.Investigational
GemifloxacinSorafenib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Sorafenib.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Sorafenib.Experimental
GliclazideThe metabolism of Gliclazide can be decreased when combined with Sorafenib.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Sorafenib.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Sorafenib.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Sorafenib.Approved
GoserelinSorafenib may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronSorafenib may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Sorafenib.Approved, Investigational
HaloperidolSorafenib may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Sorafenib.Approved, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sorafenib.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sorafenib.Approved, Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sorafenib.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Sorafenib.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sorafenib.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Sorafenib.Approved
IbutilideSorafenib may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sorafenib.Approved
IdelalisibThe serum concentration of Sorafenib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Sorafenib.Approved
IloperidoneSorafenib may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Sorafenib can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Sorafenib.Approved
IndinavirThe serum concentration of Sorafenib can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Sorafenib.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Sorafenib.Approved, Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Sorafenib.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Sorafenib.Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Sorafenib.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Sorafenib.Approved, Investigational
IsavuconazoniumThe metabolism of Sorafenib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Sorafenib.Approved, Vet Approved
IsradipineThe metabolism of Sorafenib can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Sorafenib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sorafenib can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Sorafenib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Sorafenib.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sorafenib.Approved, Investigational
KetoconazoleThe serum concentration of Sorafenib can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Sorafenib.Approved, Vet Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Sorafenib.Experimental
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Sorafenib.Approved, Investigational
LapatinibThe metabolism of Sorafenib can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Sorafenib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Sorafenib is combined with Leflunomide.Approved, Investigational
LenvatinibSorafenib may increase the QTc-prolonging activities of Lenvatinib.Approved
LesinuradThe metabolism of Lesinurad can be decreased when combined with Sorafenib.Approved
LeuprolideSorafenib may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinSorafenib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Sorafenib.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sorafenib.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Sorafenib.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Sorafenib.Approved
LopinavirThe serum concentration of Sorafenib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Sorafenib.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Sorafenib.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Sorafenib.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Sorafenib.Approved
LovastatinThe metabolism of Sorafenib can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Sorafenib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sorafenib can be increased when it is combined with Lumacaftor.Approved
LumefantrineSorafenib may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sorafenib.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Sorafenib.Illicit, Investigational, Withdrawn
MalathionThe metabolism of Malathion can be decreased when combined with Sorafenib.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Sorafenib.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Sorafenib.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sorafenib.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sorafenib.Investigational, Withdrawn
MestranolThe metabolism of Mestranol can be decreased when combined with Sorafenib.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Sorafenib.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Sorafenib.Experimental
MethadoneSorafenib may increase the QTc-prolonging activities of Methadone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sorafenib.Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Sorafenib.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Sorafenib.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Sorafenib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Sorafenib.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Sorafenib.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Sorafenib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Sorafenib.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Sorafenib.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Sorafenib.Approved, Investigational
MidazolamThe metabolism of Midazolam can be decreased when combined with Sorafenib.Approved, Illicit
MifepristoneThe serum concentration of Sorafenib can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sorafenib.Approved
MitotaneThe serum concentration of Sorafenib can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Sorafenib.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Sorafenib.Approved
MoxifloxacinSorafenib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sorafenib.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Sorafenib.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Sorafenib.Approved, Investigational
NefazodoneThe serum concentration of Sorafenib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Sorafenib can be increased when it is combined with Nelfinavir.Approved
NeomycinThe serum concentration of Sorafenib can be decreased when it is combined with Neomycin.Approved, Vet Approved
NetupitantThe serum concentration of Sorafenib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Sorafenib can be decreased when it is combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Sorafenib.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Sorafenib.Approved
NilotinibSorafenib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sorafenib.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sorafenib.Approved
OfloxacinSorafenib may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Sorafenib can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Sorafenib.Experimental, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Sorafenib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
OndansetronSorafenib may increase the QTc-prolonging activities of Ondansetron.Approved
OsimertinibThe serum concentration of Sorafenib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Sorafenib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Sorafenib.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Sorafenib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Sorafenib can be increased when it is combined with Palbociclib.Approved
PaliperidoneSorafenib may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatSorafenib may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Sorafenib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Sorafenib.Approved
ParoxetineThe metabolism of Sorafenib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sorafenib.Approved
PentamidineSorafenib may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe serum concentration of Sorafenib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerflutrenSorafenib may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Sorafenib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sorafenib.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Sorafenib.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sorafenib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Sorafenib.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Sorafenib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sorafenib.Withdrawn
PhenobarbitalThe serum concentration of Sorafenib can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sorafenib.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Sorafenib.Approved, Vet Approved
PhenytoinThe serum concentration of Sorafenib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sorafenib.Approved, Investigational
PimozideSorafenib may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Sorafenib.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sorafenib.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Sorafenib.Approved
PosaconazoleThe serum concentration of Sorafenib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sorafenib.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Sorafenib.Approved
PrimaquineSorafenib may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Sorafenib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideSorafenib may increase the QTc-prolonging activities of Procainamide.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Sorafenib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Sorafenib.Approved
PromazineSorafenib may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Sorafenib.Approved
PropacetamolSorafenib may increase the hepatotoxic activities of Propacetamol.Approved, Investigational
PropafenoneSorafenib may increase the QTc-prolonging activities of Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Sorafenib.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Sorafenib.Approved
QuazepamThe serum concentration of Sorafenib can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineSorafenib may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineSorafenib may increase the QTc-prolonging activities of Quinidine.Approved
QuinineSorafenib may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Sorafenib can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Sorafenib is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sorafenib.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sorafenib.Approved, Investigational
RifabutinThe serum concentration of Sorafenib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Sorafenib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Sorafenib can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Sorafenib.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Sorafenib.Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Sorafenib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Sorafenib.Approved
RolapitantThe serum concentration of Sorafenib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Sorafenib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Sorafenib.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Sorafenib.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sorafenib.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Sorafenib.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Sorafenib.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Sorafenib.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Sorafenib.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Sorafenib.Approved
SaquinavirThe serum concentration of Sorafenib can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Sorafenib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sorafenib.Approved
SertralineThe metabolism of Sertraline can be decreased when combined with Sorafenib.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Sorafenib.Approved, Vet Approved
SildenafilThe metabolism of Sorafenib can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Sorafenib.Approved
SiltuximabThe serum concentration of Sorafenib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sorafenib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Sorafenib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sorafenib.Approved
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Sorafenib.Approved, Investigational, Withdrawn
SotalolSorafenib may increase the QTc-prolonging activities of Sotalol.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Sorafenib.Investigational
St. John's WortThe serum concentration of Sorafenib can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Sorafenib can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Sorafenib.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Sorafenib.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Sorafenib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Sorafenib.Approved
SulfisoxazoleSorafenib may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Sorafenib.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Sorafenib.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Sorafenib.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sorafenib.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Sorafenib.Investigational
TelaprevirThe serum concentration of Sorafenib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinSorafenib may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Sorafenib can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Sorafenib.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Sorafenib.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Sorafenib.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sorafenib.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Sorafenib.Experimental
TeriflunomideThe serum concentration of Sorafenib can be increased when it is combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sorafenib.Approved, Investigational
TetrabenazineSorafenib may increase the QTc-prolonging activities of Tetrabenazine.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Sorafenib.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sorafenib.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sorafenib.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Sorafenib.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Sorafenib.Approved, Withdrawn
ThiotepaThe metabolism of Sorafenib can be decreased when combined with Thiotepa.Approved
TiclopidineThe metabolism of Sorafenib can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Sorafenib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibSorafenib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Sorafenib.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sorafenib.Approved, Investigational
TopiroxostatThe metabolism of Sorafenib can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sorafenib.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Sorafenib.Approved
ToremifeneSorafenib may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Sorafenib.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Sorafenib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sorafenib.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Sorafenib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sorafenib.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sorafenib.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Sorafenib.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sorafenib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sorafenib.Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Sorafenib.Approved, Investigational, Nutraceutical
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Sorafenib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Sorafenib.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Sorafenib.Approved, Investigational
VandetanibSorafenib may increase the QTc-prolonging activities of Vandetanib.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Sorafenib.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Sorafenib.Approved
VemurafenibSorafenib may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Sorafenib can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Sorafenib can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Sorafenib.Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Sorafenib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Sorafenib.Approved
VoriconazoleThe serum concentration of Sorafenib can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sorafenib.Approved
WarfarinSorafenib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Sorafenib.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Sorafenib.Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Sorafenib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sorafenib.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Sorafenib.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Sorafenib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Sorafenib.Approved, Investigational, Withdrawn
ZiprasidoneSorafenib may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sorafenib.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Sorafenib.Approved
ZuclopenthixolSorafenib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Ales Gavenda, Alexandr Jegorov, Pierluigi Rossetto, Peter Lindsay MacDonald, Augusto Canavesi, "POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF." U.S. Patent US20090192200, issued July 30, 2009.

US20090192200
General References
Not Available
External Links
Human Metabolome Database
HMDB14542
KEGG Drug
D08524
PubChem Compound
216239
PubChem Substance
46505329
ChemSpider
187440
BindingDB
16673
ChEBI
50924
ChEMBL
CHEMBL1336
Therapeutic Targets Database
DAP000006
PharmGKB
PA7000
HET
BAX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sorafenib
ATC Codes
L01XE05 — Sorafenib
AHFS Codes
  • 92:00.00 — Miscellaneous Therapeutic Agents
PDB Entries
1uwh / 1uwj / 3gcs / 3heg / 3rgf / 3wze / 4asd / 5hi2
FDA label
Download (310 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentRenal Cancers1
0TerminatedTreatmentHepatocellular,Carcinoma1
1Active Not RecruitingTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / BCLC Stage B Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma1
1Active Not RecruitingTreatmentCancer, Advanced2
1Active Not RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1Active Not RecruitingTreatmentHepatocellular,Carcinoma3
1Active Not RecruitingTreatmentHepatocellular,Carcinoma / Malignant Neoplasm of Pancreas1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentLiver Cancer2
1Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentOcular Melanoma1
1Active Not RecruitingTreatmentSarcomas1
1Active Not RecruitingTreatmentTumors Metastatic to Brain1
1Active Not RecruitingTreatmentTumors, Solid1
1CompletedNot AvailableAdvanced Solid Tumors / Refractory to Standard Therapies1
1CompletedNot AvailableDrug Interactions1
1CompletedNot AvailableNeoplasms1
1CompletedBasic ScienceKidney Diseases1
1CompletedBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1CompletedHealth Services ResearchFasting1
1CompletedOtherBiological Availability1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Leukemias1
1CompletedTreatmentAcute Promyelocytic Leukemia (APL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1CompletedTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Blastic Phase / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
1CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1CompletedTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma1
1CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Resectable Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Malignant Neoplasm1
1CompletedTreatmentAdvanced Solid Tumors3
1CompletedTreatmentAdvanced Solid Tumors / Malignant Lymphomas1
1CompletedTreatmentBiphenotypic Leukemia / Infantile Leukemia (Both AML and ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentBladder Cancers1
1CompletedTreatmentCancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Mesothelioma / Prostate Cancer / Sarcomas1
1CompletedTreatmentCancers2
1CompletedTreatmentCarcinoid Tumors / Neuroendocrine Tumors / Progressive Neuroendocrine Tumors of pancreatic origin1
1CompletedTreatmentCarcinoma NOS1
1CompletedTreatmentCarcinoma, Small Cell / Lung Cancers1
1CompletedTreatmentEwing's Sarcoma Family of Tumors / Neoplasms, Brain / Neuroblastomas / Rhabdomyosarcoma and Other Soft Tissue Sarcomas / Sarcoma, Osteogenic1
1CompletedTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentGastrointestinal Tumors / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentHepatocellular Cancer1
1CompletedTreatmentHepatocellular Cancer / Liver Cancer1
1CompletedTreatmentHepatocellular,Carcinoma9
1CompletedTreatmentHepatocellular,Carcinoma / Liver Cancer / Localized Unresectable Liver Cancer1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1CompletedTreatmentLeukemias / Refractory Solid Tumors1
1CompletedTreatmentLiver Diseases1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Relapsed and/or Refractory Solid Tumors / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMalignant Neoplasm of Stomach1
1CompletedTreatmentMalignant Solid Tumours / Non Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMelanoma (Skin)1
1CompletedTreatmentMelanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
1CompletedTreatmentMelanoma / Renal Cancers1
1CompletedTreatmentMetastatic Brain Tumors / Primary Brain Tumors1
1CompletedTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentNeoplasms4
1CompletedTreatmentPrimary Disease / Prostate Cancer1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
1CompletedTreatmentRectal Carcinoma1
1CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
1CompletedTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1CompletedTreatmentRefractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Stage III Multiple Myeloma / Stage IV Chronic Lymphocytic Leukemia / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRefractory Malignancy1
1CompletedTreatmentRefractory Solid Tumors1
1CompletedTreatmentRenal Cancers / Tumors1
1CompletedTreatmentRenal Cell Adenocarcinoma1
1CompletedTreatmentT Cell Lymphomas1
1CompletedTreatmentTumors, Solid3
1CompletedTreatmentUnresectable or Metastatic Hepatocellular Carcinoma (HCC)1
1CompletedTreatmentUnspecified Adult Solid Tumor1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific4
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hematopoietic/Lymphoid Cancer / Leukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Carcinoma / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAdvanced Solid Tumors / Hepatocellular,Carcinoma1
1RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer1
1RecruitingTreatmentCancer, Breast / Metastatic Brain Tumors1
1RecruitingTreatmentChild-Pugh Class A / Child-Pugh Class B / Hepatitis B Infection / Hepatitis C Infection / Liver Cirrhosis / Metastatic Malignant Solid Neoplasm / Recurrent Hepatocellular Carcinoma / Recurrent Malignant Solid Neoplasm / Refractory Malignant Neoplasm / Solid Neoplasms / Stage IV Hepatocellular Carcinoma / Stage IV Hepatocellular Carcinoma AJCC v7 / Unresectable Solid Neoplasm1
1RecruitingTreatmentHepatocellular Cancer / Liver Cancer1
1RecruitingTreatmentHepatocellular,Carcinoma1
1RecruitingTreatmentHepatocellular,Carcinoma / Liver Cancer / Unresectable Hepatocellular Carcinoma1
1RecruitingTreatmentNeoplasms1
1RecruitingTreatmentNeuroblastomas2
1RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
1TerminatedBasic ScienceRenal Cell Adenocarcinoma1
1TerminatedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Blastic Phase Chronic Myelogenous Leukemia / Recurrent Adult Acute Myeloid Leukemia / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentHHV-8 / Kaposi s Sarcoma (KS) / KSHV1
1TerminatedTreatmentHepatocellular,Carcinoma3
1TerminatedTreatmentLiver Cancer2
1TerminatedTreatmentLung Cancers1
1TerminatedTreatmentMetastatic Colorectal Cancers1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentRenal Cancers1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentHepatocellular,Carcinoma1
1Unknown StatusTreatmentMetastatic or Locally Advanced Solid Tumors1
1WithdrawnNot AvailableLocally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)1
1WithdrawnTreatmentAdvanced Cancers1
1WithdrawnTreatmentHepatocellular Cancer1
1WithdrawnTreatmentHepatocellular Cancer / Hepatocellular,Carcinoma / Liver Cancer1
1WithdrawnTreatmentHepatocellular,Carcinoma1
1, 2Active Not RecruitingTreatmentAdenoma, Liver Cell / Hepatocellular,Carcinoma / Liver Neoplasms, Experimental / Neoplasms, Hepatic1
1, 2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1, 2Active Not RecruitingTreatmentCancers / Liver Metastasis1
1, 2Active Not RecruitingTreatmentHepatocellular,Carcinoma3
1, 2Active Not RecruitingTreatmentHepatocellular,Carcinoma / Liver Cancer1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1, 2Active Not RecruitingTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1, 2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2CompletedNot AvailableRenal Cell Adenocarcinoma1
1, 2CompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentAdvanced Gastric Cancer1
1, 2CompletedTreatmentAdvanced Hepatocellular Carcinoma1
1, 2CompletedTreatmentAdvanced Liver Cancer / Metastatic Hepatocellular Carcinoma1
1, 2CompletedTreatmentBile Duct Neoplasms / Neoplasms, Pancreatic1
1, 2CompletedTreatmentBiliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer1
1, 2CompletedTreatmentCancer of the Cervix1
1, 2CompletedTreatmentCancer, Advanced1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentChromophobe Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Papillary Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Sarcomatoid Renal Cell Carcinoma / Stage IV Renal Cell Cancer1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentHepatocellular,Carcinoma3
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Disorders1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / With AML and FLT3-ITD Mutations1
1, 2CompletedTreatmentLiver Cancer1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)1
1, 2CompletedTreatmentMetastatic Colorectal Cancers1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentRenal Cancers1
1, 2CompletedTreatmentRenal Cell Adenocarcinoma2
1, 2CompletedTreatmentSoft Tissue Sarcoma (STS)1
1, 2CompletedTreatmentSquamous Cell Cancer1
1, 2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / De Novo Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms1
1, 2RecruitingTreatmentAdvanced Adult Hepatocellular Carcinoma / Child-Pugh Class A / Stage III Hepatocellular Carcinoma / Stage IIIA Hepatocellular Carcinoma / Stage IIIB Hepatocellular Carcinoma / Stage IIIC Hepatocellular Carcinoma / Stage IV Hepatocellular Carcinoma / Stage IVA Hepatocellular Carcinoma / Stage IVB Hepatocellular Carcinoma1
1, 2RecruitingTreatmentAnaplastic Gliomas / Glioblastomas / Neoplasms, Brain1
1, 2RecruitingTreatmentHCC / Hepatocellular,Carcinoma / Liver Cancer1
1, 2RecruitingTreatmentHepatocellular,Carcinoma3
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2SuspendedTreatmentAdvanced Solid Tumors1
1, 2SuspendedTreatmentLiver Cancer / Renal Cancers1
1, 2TerminatedTreatmentCancer, Ovarian1
1, 2TerminatedTreatmentHepatocellular,Carcinoma3
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2TerminatedTreatmentLung Cancers1
1, 2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2TerminatedTreatmentProstate Cancer1
1, 2Unknown StatusTreatmentHepatocellular,Carcinoma1
1, 2Unknown StatusTreatmentMelanoma (Skin)2
1, 2Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
1, 2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
1, 2WithdrawnTreatmentAdvanced Hepatocellular Carcinoma1
1, 2WithdrawnTreatmentHepatocellular,Carcinoma1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (Megakaryoblastic) With t(1;22)(p13;q13); RBM15-MKL1 / Acute Myeloid Leukemia With a Variant RARA Translocation / Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214 / Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Acute Myeloid Leukemia With Variant MLL Translocations / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Primary Hepatocellular Carcinoma / Localized Resectable Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
2Active Not RecruitingTreatmentCHILD B / Hepatocellular,Carcinoma1
2Active Not RecruitingTreatmentCancer, Breast2
2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
2Active Not RecruitingTreatmentGastrointestinal Stromal Tumors1
2Active Not RecruitingTreatmentHCC1
2Active Not RecruitingTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
2Active Not RecruitingTreatmentHepatocellular Cancer1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma5
2Active Not RecruitingTreatmentLiver Cancer2
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentMultiple Endocrine Neoplasia / Recurrent Thyroid Gland Carcinoma / Thyroid Gland Medullary Carcinoma1
2Active Not RecruitingTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V71
2Active Not RecruitingTreatmentThyroid Cancers1
2Active Not RecruitingTreatmentUveal Melanoma1
2CompletedSupportive CareNeuroendocrine Tumors1
2CompletedTreatmentAdenocarcinoma of the Extrahepatic Bile Duct / Adenocarcinoma of the Gallbladder / Adenocarcinoma With Squamous Metaplasia of the Gallbladder / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Squamous Cell Carcinoma of the Gallbladder / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate1
2CompletedTreatmentAdenocarcinoma of the Prostate / Stage II Prostate Cancer / Stage III Prostate Cancer1
2CompletedTreatmentAdenocarcinomas1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
2CompletedTreatmentAdult Angiosarcoma / Adult Epithelioid Sarcoma / Adult Leiomyosarcoma / Adult Malignant Fibrous Histiocytoma / Adult Neurofibrosarcoma / Adult Synovial Sarcoma / Ovarian Sarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Uterine Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage III Uterine Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Stage IV Uterine Sarcoma / Uterine Carcinosarcoma / Uterine Leiomyosarcoma1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma / Hepatic neoplasms malignant / Liver Cancer / Neoplasms, Hepatic1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma / Inoperable Hepatocellular Carcinoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma1
2CompletedTreatmentAdvanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)1
2CompletedTreatmentAnaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma1
2CompletedTreatmentAnaplastic Large Cell Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma1
2CompletedTreatmentBladder Cancers1
2CompletedTreatmentCancer, Breast2
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian2
2CompletedTreatmentCancers / Melanoma1
2CompletedTreatmentCancers / Non-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentChildhood Hepatocellular Carcinoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Rhabdomyosarcoma / Recurrent Thyroid Cancer / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Thyroid Papillary Carcinoma1
2CompletedTreatmentChronic Myelogenous Leukemia (CML)1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Metastatic Intraocular Melanoma / Recurrent Intraocular Melanoma1
2CompletedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer1
2CompletedTreatmentClinically Significant Portal Hypertension1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentEffects of Chemotherapy / Malignant Neoplasm of Stomach1
2CompletedTreatmentEpithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma / Stage IA Malignant Mesothelioma / Stage IB Malignant Mesothelioma / Stage II Malignant Mesothelioma / Stage III Malignant Mesothelioma / Stage IV Malignant Mesothelioma1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer1
2CompletedTreatmentExtrahepatic Bile Duct Adenocarcinoma / Gallbladder Adenocarcinoma / Gallbladder Adenocarcinoma With Squamous Metaplasia / Hilar Cholangiocarcinoma / Recurrent Extrahepatic Bile Duct Carcinoma / Recurrent Gallbladder Carcinoma / Undifferentiated Gallbladder Carcinoma / Unresectable Extrahepatic Bile Duct Carcinoma / Unresectable Gallbladder Carcinoma1
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
2CompletedTreatmentFallopian Tube Cancer / Neoplasms, Ovarian / Primary Peritoneal Cancer1
2CompletedTreatmentGastrinoma / Glucagonoma / Insulinoma / Metastatic Gastrointestinal Carcinoid Tumor / Neuroendocrine Tumors / Pancreatic Polypeptide Tumor / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma / WDHA Syndrome1
2CompletedTreatmentGastrointestinal Stromal Tumors1
2CompletedTreatmentGlioblastoma Multiforme1
2CompletedTreatmentHepatocellular,Carcinoma13
2CompletedTreatmentKidney Diseases / Renal Cancers / Renal Cell Adenocarcinoma1
2CompletedTreatmentLeiomyosarcomas / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas / Synovial Sarcoma1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)2
2CompletedTreatmentLiver Cancer2
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
2CompletedTreatmentLung Cancers4
2CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMalignant Melanoma2
2CompletedTreatmentMalignant Neoplasm of Pancreas2
2CompletedTreatmentMelanoma2
2CompletedTreatmentMelanoma Stage III or IV / No Prior Chemotherapy1
2CompletedTreatmentMetastasis / Neoplasms1
2CompletedTreatmentMetastatic Anaplastic Thyroid Cancer / Metastatic Differentiated Thyroid Cancer / Metastatic Medullary Thyroid Cancer / Metastatic Poorly Differentiated Thyroid Cancer1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Cancers / Renal Cancers1
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMetastatic Disease / Renal Cell Adenocarcinoma2
2CompletedTreatmentMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Osteosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Osteosarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentMetastatic Osteosarcoma / Relapsed Osteosarcoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary2
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2CompletedTreatmentNeoplasms, Head and Neck1
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentPrimary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentRecurrent Glioblastoma Multiforme1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Melanoma / Stage IV Skin Melanoma / Stages III Skin Melanoma1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer1
2CompletedTreatmentRecurrent Uterine Sarcoma / Stage III Uterine Sarcoma / Stage IV Uterine Sarcoma / Uterine Carcinosarcoma1
2CompletedTreatmentRefractory Multiple Myeloma1
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentRenal Cell Adenocarcinoma7
2CompletedTreatmentSarcoma, Osteogenic1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentStage III Melanoma / Stage IV Melanoma1
2CompletedTreatmentStage IV Pancreatic Cancer1
2CompletedTreatmentThyroid Cancers1
2CompletedTreatmentThyroid Carcinoma1
2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2Not Yet RecruitingTreatmentHepatocellular Cancer1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentBrain and Nervous System / Glioblastomas / Gliomas / Malignant Gliomas / Recurrent Adult Brain Neoplasm / WHO Grade III Glioma1
2RecruitingTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
2RecruitingTreatmentCholangiocarcinoma of the Extrahepatic Bile Duct / Gallbladder Cancer1
2RecruitingTreatmentHepatocellular Cancer1
2RecruitingTreatmentHepatocellular Carcinoma (HCC)1
2RecruitingTreatmentHepatocellular,Carcinoma2
2RecruitingTreatmentHepatocellular,Carcinoma / Portal Vein Thrombosis1
2RecruitingTreatmentHepatocellular,Carcinoma / Secondary1
2RecruitingTreatmentHepatopulmonary Syndrome1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentMalignant Solid Neoplasms1
2RecruitingTreatmentMetastatic Colorectal Cancer Patients With KRAS Mutated Tumors1
2RecruitingTreatmentMetastatic Renal Cell Carcinoma2
2RecruitingTreatmentPediatric Solid Tumors1
2RecruitingTreatmentRefractory Hurthle Cell Thyroid Cancer1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentStage IIB Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentThyroid Cancers1
2TerminatedTreatmentAdenocarcinoma of the Bladder / Distal Urethral Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Squamous Cell Carcinoma of the Bladder / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2TerminatedTreatmentAdvanced Hepatocellular Carcinoma1
2TerminatedTreatmentAnaplastic Thyroid Cancers / Insular Thyroid Cancer / Recurrent Thyroid Cancer / Stage III Follicular Thyroid Cancer / Stage III Papillary Thyroid Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Papillary Thyroid Cancer1
2TerminatedTreatmentAnaplastic Thyroid Cancers / Recurrent Thyroid Cancer1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer, Breast5
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2TerminatedTreatmentClear Cell Renal Cell Carcinoma / Papillary Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2TerminatedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
2TerminatedTreatmentHepatocellular,Carcinoma5
2TerminatedTreatmentKeloid Scars1
2TerminatedTreatmentLeukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
2TerminatedTreatmentLiver Cancer1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non Squamous Cell Lung Cancer1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentLung Cancers2
2TerminatedTreatmentMalignant Neoplasm of Stomach1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentMetastatic Hormone Refractory Prostate Cancer1
2TerminatedTreatmentMetastatic Renal Cell Carcinoma3
2TerminatedTreatmentNeoplasms, Colorectal1
2TerminatedTreatmentNeurofibromatosis1 (NF1) / Recurrent or Progressive Low-grade Glioma / Recurrent or Progressive Optic Pathway Gliomas (OPG)1
2TerminatedTreatmentRefractory Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentRenal Cell Adenocarcinoma4
2TerminatedTreatmentSarcomas1
2Unknown StatusDiagnosticSalivary Gland Cancers1
2Unknown StatusTreatmentAdrenocortical Carcinoma1
2Unknown StatusTreatmentBladder Cancers1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentHepatocellular,Carcinoma5
2Unknown StatusTreatmentHepatocellular,Carcinoma / Metastasis1
2Unknown StatusTreatmentLiver Cancer2
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Unknown StatusTreatmentLung Cancers1
2Unknown StatusTreatmentMelanoma (Skin)2
2Unknown StatusTreatmentMesothelioma1
2Unknown StatusTreatmentNeoplasms, Colorectal1
2Unknown StatusTreatmentProstate Cancer1
2Unknown StatusTreatmentRenal Cell Adenocarcinoma2
2Unknown StatusTreatmentSarcomas1
2Unknown StatusTreatmentTesticular Cancer1
2WithdrawnTreatmentGlioblastomas / Gliosarcoma1
2WithdrawnTreatmentHepatocellular,Carcinoma1
2WithdrawnTreatmentLocally Metastatic Malignant Neoplasm1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMedullary Thyroid Cancer (MTC)1
2WithdrawnTreatmentMelanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
2WithdrawnTreatmentProstate Cancer1
2, 3CompletedTreatmentHepatocellular,Carcinoma1
2, 3RecruitingTreatmentHCC1
2, 3RecruitingTreatmentHematopoietic Stem Cell Transplantation (HSCT) / Leukemia Acute Myeloid Leukemia (AML)1
2, 3RecruitingTreatmentHepatocellular,Carcinoma2
2, 3RecruitingTreatmentLiver Cancer1
2, 3Unknown StatusTreatmentQuality of Life1
3Active Not RecruitingTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma / BCLC Stage D Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Non-Resectable Hepatocellular Carcinoma / Recurrent Adult Liver Carcinoma / Recurrent Hepatocellular Carcinoma / Stage III Hepatocellular Carcinoma AJCC v7 / Stage IIIA Hepatocellular Carcinoma AJCC v7 / Stage IIIB Hepatocellular Carcinoma AJCC v7 / Stage IIIC Hepatocellular Carcinoma AJCC v7 / Stage IV Hepatocellular Carcinoma AJCC v7 / Stage IVA Hepatocellular Carcinoma AJCC v7 / Stage IVB Hepatocellular Carcinoma AJCC v71
3Active Not RecruitingTreatmentCancer, Breast1
3Active Not RecruitingTreatmentDesmoid-Type Fibromatosis1
3Active Not RecruitingTreatmentGranulocytic Sarcoma / Leukaemia cutis / Leukemia Acute Myeloid Leukemia (AML) / Myeloid Neoplasm / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3Active Not RecruitingTreatmentHepatocellular Carcinoma (HCC)1
3Active Not RecruitingTreatmentHepatocellular,Carcinoma3
3Active Not RecruitingTreatmentHepatocellular,Carcinoma / Non-Resectable Hepatocellular Carcinoma1
3Active Not RecruitingTreatmentNeoplasms, Kidney1
3Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
3CompletedTreatmentAdvanced Renal Cell Carcinoma2
3CompletedTreatmentCarcinoma NOS / Non-Small-Cell Lung1
3CompletedTreatmentChild-Pugh A Hepatocellular Carcinoma1
3CompletedTreatmentClear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer / Stage II Renal Cell Cancer / Stage III Renal Cell Cancer1
3CompletedTreatmentHepato Cellular Carcinoma (HCC)1
3CompletedTreatmentHepatocellular,Carcinoma5
3CompletedTreatmentLiver Cancer1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentMelanoma1
3CompletedTreatmentMetastatic Renal Cell Carcinoma2
3CompletedTreatmentMucosal Melanoma / Recurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
3CompletedTreatmentNeoplasms, Kidney1
3CompletedTreatmentNeoplasms, Thyroid1
3CompletedTreatmentRenal Cancers1
3CompletedTreatmentRenal Cell Adenocarcinoma8
3Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
3RecruitingTreatmentHCC1
3RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3RecruitingTreatmentHepatocellular Carcinoma (HCC)1
3RecruitingTreatmentHepatocellular,Carcinoma3
3RecruitingTreatmentHepatocellular,Carcinoma / I.V Advanced Cancer1
3RecruitingTreatmentHepatocellular,Carcinoma / Recurrences1
3RecruitingTreatmentNeoplasms1
3TerminatedTreatmentAdenocarcinomas / Carcinoma NOS / Digestive System Diseases / Digestive System Neoplasms / Hepatocellular Carcinoma Non-resectable / Hepatocellular Carcinoma Recurrent / Hepatocellular,Carcinoma / Liver Diseases / Neoplasms / Neoplasms by Histologic Type / Neoplasms by Site / Neoplasms, Glandular and Epithelial / Neoplasms, Hepatic1
3TerminatedTreatmentAdvanced Adult Hepatocellular Carcinoma1
3TerminatedTreatmentHepatocellular,Carcinoma1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3Unknown StatusTreatmentAdvanced Hepatocellular Carcinoma / Carcinoma NOS / Hepatocellular,Carcinoma / Neoplasms / Neoplasms, Hepatic1
3Unknown StatusTreatmentLiver Cancer1
3Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
3WithdrawnTreatmentHepatic neoplasms malignant1
4CompletedTreatmentHepatocellular,Carcinoma2
4RecruitingBasic ScienceHepatocellular,Carcinoma1
4RecruitingPreventionPortal Vein Tumor Thrombus1
4RecruitingTreatmentHepatectomy / Hepatocellular,Carcinoma / Sorafenib1
4RecruitingTreatmentHepatocellular,Carcinoma1
4Unknown StatusTreatmentHepatocellular Cancer1
4WithdrawnNot AvailableRenal Cell Adenocarcinoma1
Not AvailableActive Not RecruitingNot AvailableRenal Cell Adenocarcinoma1
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingTreatmentAcute myeloid leukaemia (in remission) / Acute Myeloid Leukemia With FLT3/ITD Mutation / Adult Acute Myeloid Leukemia in Remission1
Not AvailableActive Not RecruitingTreatmentAdvanced Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Hepatocellular Carcinoma / Stage III Childhood Hepatocellular Carcinoma / Stage IIIA Hepatocellular Carcinoma / Stage IIIB Hepatocellular Carcinoma / Stage IIIC Hepatocellular Carcinoma / Stage IV Childhood Hepatocellular Carcinoma / Stage IVA Hepatocellular Carcinoma / Stage IVB Hepatocellular Carcinoma1
Not AvailableActive Not RecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableActive Not RecruitingTreatmentRefractory Solid Tumors1
Not AvailableCompletedNot AvailableCarcinoma, Renal Cell (Advanced) / Renal Cell Adenocarcinoma2
Not AvailableCompletedNot AvailableChildhood Acute Myeloid Leukemia/Other Myeloid Malignancies1
Not AvailableCompletedNot AvailableHepatocellular,Carcinoma8
Not AvailableCompletedNot AvailableHepatocellular,Carcinoma / Renal Cell Adenocarcinoma1
Not AvailableCompletedNot AvailableRenal Cell Adenocarcinoma8
Not AvailableCompletedBasic ScienceClear Cell Renal Cell Carcinoma1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentRefractory Solid Tumors1
Not AvailableNot Yet RecruitingTreatmentHCC1
Not AvailableRecruitingNot AvailableHepatocellular,Carcinoma / Neuroendocrine Tumors1
Not AvailableRecruitingNot AvailableNeoplasms, Thyroid1
Not AvailableRecruitingNot AvailableThyroid Carcinoma1
Not AvailableRecruitingTreatmentHepatocellular,Carcinoma5
Not AvailableTerminatedNot AvailableColorectal Cancers / Hepatocellular Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Renal Cell Adenocarcinoma1
Not AvailableTerminatedTreatmentEsophageal Cancers1
Not AvailableTerminatedTreatmentHepatocellular,Carcinoma / Liver Cancer1
Not AvailableTerminatedTreatmentHepatocellular,Carcinoma / Liver Cell Carcinoma1
Not AvailableTerminatedTreatmentHereditary Clear Cell Renal Cell Carcinoma / Renal Cancers1
Not AvailableTerminatedTreatmentLeptomeningeal Metastases1
Not AvailableUnknown StatusNot AvailableLiver Cancer / Renal Cancers1

Pharmacoeconomics

Manufacturers
  • Bayer healthcare pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral200 mg
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral200 mg
Prices
Unit descriptionCostUnit
Nexavar 200 mg tablet66.61USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2315715No2010-06-222018-12-22Canada
CA2359510No2007-02-132020-01-12Canada
US8618141No2003-02-112023-02-11Us
US8877933No2007-12-242027-12-24Us
US8124630No2000-01-122020-01-12Us
US8841330No2000-01-122020-01-12Us
US7235576No2000-01-122020-01-12Us
US7897623No2000-01-122020-01-12Us
US7351834No2000-01-122020-01-12Us
US9737488No2008-09-102028-09-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsolubleFDA label
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00171 mg/mLALOGPS
logP4.12ALOGPS
logP4.34ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.55ChemAxon
pKa (Strongest Basic)2.03ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area92.35 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity114.52 m3·mol-1ChemAxon
Polarizability41.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9649
Blood Brain Barrier+0.851
Caco-2 permeable-0.5138
P-glycoprotein substrateNon-substrate0.5086
P-glycoprotein inhibitor INon-inhibitor0.7141
P-glycoprotein inhibitor IINon-inhibitor0.9359
Renal organic cation transporterNon-inhibitor0.8938
CYP450 2C9 substrateNon-substrate0.6569
CYP450 2D6 substrateNon-substrate0.8212
CYP450 3A4 substrateNon-substrate0.5341
CYP450 1A2 substrateInhibitor0.6168
CYP450 2C9 inhibitorNon-inhibitor0.6171
CYP450 2D6 inhibitorNon-inhibitor0.9145
CYP450 2C19 inhibitorInhibitor0.637
CYP450 3A4 inhibitorNon-inhibitor0.7339
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6629
Ames testNon AMES toxic0.8143
CarcinogenicityNon-carcinogens0.8684
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7885 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9488
hERG inhibition (predictor II)Non-inhibitor0.6415
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Diarylethers
Alternative Parents
Trifluoromethylbenzenes / N-phenylureas / Pyridinecarboxamides / 2-heteroaryl carboxamides / Phenoxy compounds / Phenol ethers / Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds / Secondary carboxylic acid amides
show 10 more
Substituents
Diaryl ether / N-phenylurea / Trifluoromethylbenzene / Pyridinecarboxamide / Pyridine carboxylic acid or derivatives / Phenoxy compound / 2-heteroaryl carboxamide / Phenol ether / Halobenzene / Chlorobenzene
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, ureas, monochlorobenzenes, (trifluoromethyl)benzenes, pyridinecarboxamide (CHEBI:50924)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, a...
Gene Name
BRAF
Uniprot ID
P15056
Uniprot Name
Serine/threonine-protein kinase B-raf
Molecular Weight
84436.135 Da
References
  1. Flaherty KT: Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2366s-2370s. [PubMed:16609060]
  2. Haluska FG, Ibrahim N: Therapeutic targets in melanoma: map kinase pathway. Curr Oncol Rep. 2006 Sep;8(5):400-5. [PubMed:16901402]
  3. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN: Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther. 2007 Jun;6(6):1785-92. [PubMed:17575107]
  4. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 4;95(5):581-6. Epub 2006 Aug 1. [PubMed:16880785]
  5. Lu X, Tang X, Guo W, Ren T, Zhao H: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol. 2010 Dec 1;102(7):821-6. doi: 10.1002/jso.21661. [PubMed:20812347]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determin...
Gene Name
RAF1
Uniprot ID
P04049
Uniprot Name
RAF proto-oncogene serine/threonine-protein kinase
Molecular Weight
73051.025 Da
References
  1. Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. [PubMed:16757355]
  2. Gollob JA, Wilhelm S, Carter C, Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006 Aug;33(4):392-406. [PubMed:16890795]
  3. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol. 2007 May 1;73(9):1308-17. Epub 2007 Jan 5. [PubMed:17266941]
  4. Cascone T, Gridelli C, Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102. [PubMed:17272980]
  5. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200. [PubMed:17296815]
  6. Lu X, Tang X, Guo W, Ren T, Zhao H: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol. 2010 Dec 1;102(7):821-6. doi: 10.1002/jso.21661. [PubMed:20812347]
  7. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009 Jan 8;28(1):85-94. doi: 10.1038/onc.2008.362. Epub 2008 Sep 15. [PubMed:18794803]
  8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008 Oct;7(10):3129-40. doi: 10.1158/1535-7163.MCT-08-0013. [PubMed:18852116]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardi...
Gene Name
FLT4
Uniprot ID
P35916
Uniprot Name
Vascular endothelial growth factor receptor 3
Molecular Weight
152755.94 Da
References
  1. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P: Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25. [PubMed:16133532]
  2. Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. [PubMed:16757355]
  3. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200. [PubMed:17296815]
  4. Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc). 2005 Dec;41(12):773-84. [PubMed:16474853]
  5. Reddy GK, Bukowski RM: Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. Clin Genitourin Cancer. 2006 Mar;4(4):246-8. [PubMed:16729906]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and ...
Gene Name
KDR
Uniprot ID
P35968
Uniprot Name
Vascular endothelial growth factor receptor 2
Molecular Weight
151525.555 Da
References
  1. Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17. [PubMed:16418310]
  2. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006 Mar 20;24(9):1363-9. Epub 2006 Jan 30. [PubMed:16446323]
  3. Rini BI: Sorafenib. Expert Opin Pharmacother. 2006 Mar;7(4):453-61. [PubMed:16503817]
  4. Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. [PubMed:16757355]
  5. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadler WM: Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov;31(6):783-5. Epub 2006 Jul 4. [PubMed:16824050]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells...
Gene Name
FLT3
Uniprot ID
P36888
Uniprot Name
Receptor-type tyrosine-protein kinase FLT3
Molecular Weight
112902.51 Da
References
  1. Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM: Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007 Mar;21(3):439-45. Epub 2007 Jan 4. [PubMed:17205056]
  2. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J: The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007 Jan;92(1):27-34. [PubMed:17229632]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Vascular endothelial growth factor binding
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic...
Gene Name
PDGFRB
Uniprot ID
P09619
Uniprot Name
Platelet-derived growth factor receptor beta
Molecular Weight
123966.895 Da
References
  1. Gollob JA: Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):167-74. [PubMed:16425993]
  2. Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F: Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [PubMed:17545544]
  3. Unnithan J, Rini BI: The role of targeted therapy in metastatic renal cell carcinoma. ScientificWorldJournal. 2007 Mar 2;7:800-7. [PubMed:17619763]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell main...
Gene Name
KIT
Uniprot ID
P10721
Uniprot Name
Mast/stem cell growth factor receptor Kit
Molecular Weight
109863.655 Da
References
  1. Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F: Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [PubMed:17545544]
  2. Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK, Lamesch P, Ott R, Kluge R, Bierbach U, Tannapfel A: Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci. 2006 Aug;1073:517-26. [PubMed:17102120]
  3. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J: The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007 Jan;92(1):27-34. [PubMed:17229632]
  4. Cascone T, Gridelli C, Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102. [PubMed:17272980]
  5. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006 Dec 15;66(24):11851-8. [PubMed:17178882]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein tyrosine kinase activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation ...
Gene Name
FGFR1
Uniprot ID
P11362
Uniprot Name
Fibroblast growth factor receptor 1
Molecular Weight
91866.935 Da
References
  1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [PubMed:15466206]
  2. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. [PubMed:16507829]
  3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44. [PubMed:17016424]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell de...
Gene Name
RET
Uniprot ID
P07949
Uniprot Name
Proto-oncogene tyrosine-protein kinase receptor Ret
Molecular Weight
124317.465 Da
References
  1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [PubMed:15466206]
  2. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. [PubMed:16507829]
  3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44. [PubMed:17016424]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vegf-b-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell ...
Gene Name
FLT1
Uniprot ID
P17948
Uniprot Name
Vascular endothelial growth factor receptor 1
Molecular Weight
150767.185 Da
References
  1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [PubMed:15466206]
  2. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. [PubMed:16507829]
  3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44. [PubMed:17016424]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B: Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. doi: 10.1007/s10637-010-9514-3. Epub 2010 Aug 13. [PubMed:20706860]
  2. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  3. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B: Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. doi: 10.1007/s10637-010-9514-3. Epub 2010 Aug 13. [PubMed:20706860]
  2. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  3. Keating GM, Santoro A: Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. [PubMed:19228077]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380]
  2. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH: Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26. doi: 10.1158/1535-7163.MCT-09-0663. Epub 2010 Jan 26. [PubMed:20103600]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380]
  2. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH: Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26. doi: 10.1158/1535-7163.MCT-09-0663. Epub 2010 Jan 26. [PubMed:20103600]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transmembrane transporter activity
Specific Function
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the ma...
Gene Name
RALBP1
Uniprot ID
Q15311
Uniprot Name
RalA-binding protein 1
Molecular Weight
76062.86 Da
References
  1. Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Rao Lelsani PC, Yadav S, Awasthi S: Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38. doi: 10.1002/ijc.24767. [PubMed:19626587]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18